

Marc Bardou

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7194648/publications.pdf>

Version: 2024-02-01

97
papers

6,264
citations

159358

30
h-index

69108

77
g-index

99
all docs

99
docs citations

99
times ranked

7003
citing authors

#	ARTICLE	IF	CITATIONS
1	First use of Simulation in Therapeutic Patient Education (S-TPE) in adults with diabetes: a pilot study. <i>BMJ Open</i> , 2022, 12, e049454.	0.8	2
2	Leptin-Induced HLA-G Inhibits Myometrial Contraction and Differentiation. <i>Cells</i> , 2022, 11, 954.	1.8	1
3	Violence against women and perceived health: An observational survey of patients treated in the multidisciplinary structure "The Women's House" and two Family Planning Centres in the metropolitan Paris area. <i>Health and Social Care in the Community</i> , 2022, 30, .	0.7	2
4	Assessing the Acceptability of Home-Based HPV Self-Sampling: A Qualitative Study on Cervical Cancer Screening Conducted in Reunion Island Prior to the RESISTE Trial. <i>Cancers</i> , 2022, 14, 1380.	1.7	7
5	Review article: obesity and colorectal cancer. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 56, 407-418.	1.9	25
6	Immunogenicity and Safety of Beta-Adjuvanted Recombinant Booster Vaccine. <i>New England Journal of Medicine</i> , 2022, 387, 374-376.	13.9	44
7	An update on drug-drug interactions associated with proton pump inhibitors. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2022, 18, 337-346.	1.5	8
8	The pharmacotherapeutic management of gastroesophageal reflux disease (GERD). <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 219-227.	0.9	12
9	Relative risk rather than absolute risk reduction should be preferred to sensitise the public to preventive actions. <i>Gut</i> , 2021, , gutjnl-2021-324689.	6.1	5
10	Comparative benefit and cost-effectiveness of mailed-out faecal immunochemical tests vs collection at the general practitioner. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 1118-1125.	1.9	0
11	Editorial: "Stardust gastric mucosa" A novel and consistent marker of vonoprazan safety during follow-up?. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 196-197.	1.9	1
12	Editorial: how can we best promote the routine use of scores that are accurate at predicting outcomes in patients with upper gastrointestinal bleeding?. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 305-306.	1.9	2
13	Use of proton pump inhibitors in adults in France: a nationwide drug utilization study. <i>European Journal of Clinical Pharmacology</i> , 2020, 76, 449-457.	0.8	66
14	Participation in faecal immunochemical testing-based colorectal cancer screening programmes in the northwest of Europe. <i>Journal of Medical Screening</i> , 2020, 27, 68-76.	1.1	19
15	Recent advances in clinical practice: colorectal cancer chemoprevention in the average-risk population. <i>Gut</i> , 2020, 69, 2244-2255.	6.1	58
16	Oral anticoagulants and risk of acute liver injury in patients with nonvalvular atrial fibrillation: a propensity-weighted nationwide cohort study. <i>Scientific Reports</i> , 2020, 10, 11624.	1.6	10
17	Consensus Recommendations for the Use of Simulation in Therapeutic Patient Education. <i>Simulation in Healthcare</i> , 2020, 15, 30-38.	0.7	4
18	Bleeding, Upper Gastrointestinal; Clinical Management. , 2020, , 363-371.		0

#	ARTICLE	IF	CITATIONS
19	Monitoring HSP70 exosomes in cancer patientsâ€™ follow up: a clinical prospective pilot study. Journal of Extracellular Vesicles, 2020, 9, 1766192.	5.5	71
20	Increasing incidence of colorectal cancer in young adults in Europe over the last 25 years. Gut, 2019, 68, 1820-1826.	6.1	463
21	Secondary actionable findings identified by exome sequencing: expected impact on the organisation of care from the study of 700 consecutive tests. European Journal of Human Genetics, 2019, 27, 1197-1214.	1.4	18
22	Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group. Annals of Internal Medicine, 2019, 171, 805.	2.0	310
23	An update on the latest chemical therapies for reflux esophagitis in children. Expert Opinion on Pharmacotherapy, 2019, 20, 231-239.	0.9	9
24	Safety and efficacy of low-dose sirolimus in the PIK3CA-related overgrowth spectrum. Genetics in Medicine, 2019, 21, 1189-1198.	1.1	115
25	How can we best monitor 5-FU administration to maximize benefit to risk ratio?. Expert Opinion on Drug Metabolism and Toxicology, 2018, 14, 1303-1313.	1.5	33
26	Proton-Pump Inhibitor Prophylaxis in the ICU â€” Benefits Worth the Risks?. New England Journal of Medicine, 2018, 379, 2263-2264.	13.9	15
27	Continuous Anti-TNFÎ± Use Throughout Pregnancy: Possible Complications For the Mother But Not for the Fetus. A Retrospective Cohort on the French National Health Insurance Database (EVASION). American Journal of Gastroenterology, 2018, 113, 1669-1677.	0.2	134
28	Efficacy of a Novel Prefilled, Single-Use, Needle-Free Device (ZeneoÂ®) in Achieving Intramuscular Agent Delivery: An Observational Study. Advances in Therapy, 2017, 34, 252-260.	1.3	14
29	Beta3 adrenergic receptor stimulation in human macrophages inhibits NADPHoxidase activity and induces catalase expression via PPARÎ³ activation. Biochimica Et Biophysica Acta - Molecular Cell Research, 2017, 1864, 1769-1784.	1.9	23
30	Pharmacokinetics, pharmacodynamics and clinical efficacy of omalizumab for the treatment of asthma. Expert Opinion on Drug Metabolism and Toxicology, 2016, 12, 1503-1511.	1.5	15
31	Doseâ€‘dependent biphasic leptinâ€‘induced proliferation is caused by nonâ€‘specific <scp>IL</scp>â€‘6</scp>/<scp>NFâ€‘Î±</scp> pathway activation in human myometrial cells. British Journal of Pharmacology, 2015, 172, 2974-2990.	2.7	15
32	Changes in Maternal Blood Inflammatory Markers As a Predictor Of Chorioamnionitis: A Prospective Multicenter Study. American Journal of Reproductive Immunology, 2015, 73, 79-90.	1.2	28
33	Glutathione prevents preterm parturition and fetal death by targeting macrophageâ€‘induced reactive oxygen species production in the myometrium. FASEB Journal, 2015, 29, 2653-2666.	0.2	16
34	Role of Medical Therapy for Nonvariceal Upper Gastrointestinal Bleeding. Gastrointestinal Endoscopy Clinics of North America, 2015, 25, 463-478.	0.6	9
35	Safety of medication options for treating pediatric esophagitis. Expert Opinion on Drug Safety, 2015, 14, 1087-1096.	1.0	6
36	Systemic increase in human maternal circulating CD14+CD16â€™ MCP-1+ monocytes as a marker of labor. American Journal of Obstetrics and Gynecology, 2014, 210, 70.e1-70.e9.	0.7	19

#	ARTICLE	IF	CITATIONS
37	Pharmacokinetic evaluation of esomeprazole for the treatment of gastroesophageal reflux disease. Expert Opinion on Drug Metabolism and Toxicology, 2014, 10, 1301-1311.	1.5	3
38	Treatment of pancreatic cancer: A narrative review of cost-effectiveness studies. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2013, 27, 881-892.	1.0	26
39	Biphasic Erk1/2 activation sequentially involving Gs and Gi signaling is required in beta3-adrenergic receptor-induced primary smooth muscle cell proliferation. Biochimica Et Biophysica Acta - Molecular Cell Research, 2013, 1833, 1041-1051.	1.9	21
40	Cost-Effectiveness Analysis: Stress Ulcer Bleeding Prophylaxis with Proton Pump Inhibitors, H2 Receptor Antagonists. Value in Health, 2013, 16, 14-22.	0.1	36
41	Effects of Leptin on Lipopolysaccharide-Induced Remodeling in an In Vitro Model of Human Myometrial Inflammation1. Biology of Reproduction, 2013, 88, 45.	1.2	20
42	The increasing need for health-economic assessment in gastrointestinal and liver diseases. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2013, 27, 829-830.	1.0	2
43	Obesity and colorectal cancer. Gut, 2013, 62, 933-947.	6.1	609
44	Republished: Obesity and colorectal cancer. Postgraduate Medical Journal, 2013, 89, 519-533.	0.9	25
45	Stress Ulcer Prophylaxis in the ICU. Critical Care Medicine, 2013, 41, 906-907.	0.4	5
46	How Early Should Endoscopy Be Performed in Suspected Upper Gastrointestinal Bleeding?. American Journal of Gastroenterology, 2012, 107, 328-329.	0.2	5
47	Conflicts of Interest Ethics: Silencing Expertise in the Development of International Clinical Practice Guidelines. Annals of Internal Medicine, 2012, 156, 809.	2.0	29
48	Management of Patients With Nonvariceal Upper Gastrointestinal Bleeding. Clinical Gastroenterology and Hepatology, 2012, 10, 234-239.	2.4	36
49	Diagnosis and management of nonvariceal upper gastrointestinal bleeding. Nature Reviews Gastroenterology and Hepatology, 2012, 9, 97-104.	8.2	30
50	Incidence of Abcd1 level on the induction of cell death and organelle dysfunctions triggered by very long chain fatty acids and TNF- α on oligodendrocytes and astrocytes. NeuroToxicology, 2012, 33, 212-228.	1.4	36
51	Pharmacokinetic and clinical evaluation of esomeprazole and ASA for the prevention of gastroduodenal ulcers in cardiovascular patients. Expert Opinion on Drug Metabolism and Toxicology, 2012, 8, 1199-1208.	1.5	4
52	Is routine second-look endoscopy effective after endoscopic hemostasis in acute peptic ulcer bleeding? A meta-analysis. Gastrointestinal Endoscopy, 2012, 76, 283-292.	0.5	80
53	Proton Pump Inhibitors vs. Histamine 2 Receptor Antagonists for Stress-Related Mucosal Bleeding Prophylaxis in Critically Ill Patients: A Meta-Analysis. American Journal of Gastroenterology, 2012, 107, 507-520.	0.2	128
54	Effects of leptin on lipopolysaccharide-induced myometrial apoptosis in an in vitro human model of chorioamnionitis. American Journal of Obstetrics and Gynecology, 2011, 205, 363.e1-363.e9.	0.7	16

#	ARTICLE	IF	CITATIONS
55	The prognosis of patients having received optimal therapy for nonvariceal upper gastrointestinal bleeding might be worse in daily practice than in randomized clinical trials. <i>European Journal of Gastroenterology and Hepatology</i> , 2010, 22, 361-367.	0.8	8
56	International Consensus Recommendations on the Management of Patients With Nonvariceal Upper Gastrointestinal Bleeding. <i>Annals of Internal Medicine</i> , 2010, 152, 101.	2.0	944
57	Preventing the gastrointestinal adverse effects of nonsteroidal anti-inflammatory drugs: From risk factor identification to risk factor intervention. <i>Joint Bone Spine</i> , 2010, 77, 6-12.	0.8	32
58	Prévention des complications digestives des anti-inflammatoires non stéroïdiens: de la connaissance des facteurs de risque à leur prise en compte. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2010, 77, 7-13.	0.0	0
59	SAR150640, a selective β_3 -adrenoceptor agonist, prevents human myometrial remodelling and activation of matrix metalloproteinase in an <i>in vitro</i> model of chorioamnionitis. <i>British Journal of Pharmacology</i> , 2010, 159, 1354-1366.	2.7	18
60	Effect of statin therapy on colorectal cancer. <i>Gut</i> , 2010, 59, 1572-1585.	6.1	139
61	Prokinetics in acute upper GI bleeding: a meta-analysis. <i>Gastrointestinal Endoscopy</i> , 2010, 72, 1138-1145.	0.5	113
62	Endoscopic hemostasis in peptic ulcer bleeding for patients with high-risk lesions: a series of meta-analyses. <i>Gastrointestinal Endoscopy</i> , 2009, 69, 786-799.	0.5	164
63	Intravenous Proton Pump Inhibitors. <i>Drugs</i> , 2009, 69, 435-448.	4.9	24
64	Antitumoral Effects of Lipids A, Clinical Studies. <i>Advances in Experimental Medicine and Biology</i> , 2009, 667, 125-131.	0.8	1
65	Celecoxib but not the combination of celecoxib+atorvastatin prevents the development of monocrotaline-induced pulmonary hypertension in the rat. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2008, 378, 241-251.	1.4	13
66	Management of Acute Bleeding from a Peptic Ulcer. <i>New England Journal of Medicine</i> , 2008, 359, 928-937.	13.9	319
67	Cost-Effectiveness of Proton-Pump Inhibition Before Endoscopy in Upper Gastrointestinal Bleeding. <i>Clinical Gastroenterology and Hepatology</i> , 2008, 6, 418-425.	2.4	59
68	Pantoprazole: from drug metabolism to clinical relevance. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2008, 4, 471-483.	1.5	13
69	ADRB3 Adrenergic Receptor Is a Key Regulator of Human Myometrial Apoptosis and Inflammation During Chorioamnionitis ¹ . <i>Biology of Reproduction</i> , 2008, 78, 497-505.	1.2	23
70	In Vitro and in Vivo Pharmacological Characterization of Ethyl-4- <i>trans</i> -4-(((2 <i>S</i>)-2-hydroxy-3-(4-hydroxy-3-((methylsulfonyl)amino)-phenoxy)propyl)amino)cyclohexyl}benzoate Hydrochloride (SAR150640), a New Potent and Selective Human β_3 -Adrenoceptor Agonist for the Treatment of Preterm Labor. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2007, 321, 1118-1126.	1.3	23
71	Is the beta3-adrenoceptor (ADRB3) a potential target for uterorelaxant drugs?. <i>BMC Pregnancy and Childbirth</i> , 2007, 7, S14.	0.9	30
72	Increased superoxide anion production is associated with early atherosclerosis and cardiovascular dysfunctions in a rabbit model. <i>Molecular and Cellular Biochemistry</i> , 2007, 294, 225-235.	1.4	31

#	ARTICLE	IF	CITATIONS
73	Pro/con debate: octreotide has an important role in the treatment of gastrointestinal bleeding of unknown origin?. <i>Critical Care</i> , 2006, 10, 218.	2.5	17
74	The HMG-CoA reductase inhibitor, pravastatin, prevents the development of monocrotaline-induced pulmonary hypertension in the rat through reduction of endothelial cell apoptosis and overexpression of eNOS. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2006, 373, 401-414.	1.4	49
75	The protective effect of HMG-CoA reductase inhibitors against monocrotaline-induced pulmonary hypertension in the rat might not be a class effect: comparison of pravastatin and atorvastatin. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2006, 374, 195-206.	1.4	33
76	Meta-analysis: proton-pump inhibition in high-risk patients with acute peptic ulcer bleeding. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 21, 677-686.	1.9	130
77	SSR126768A (4-Chloro-3-[(3R)-(+)-5-chloro-1-(2,4-dimethoxybenzyl)-3-methyl-2-yl]pyridin-2-yl)amine and Orally Active Oxytocin Receptor Antagonist for the Prevention of Preterm Labor. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2004, 309, 414-424.	1.3	63
78	Nociceptin inhibits airway microvascular leakage induced by HCl intra-oesophageal instillation. <i>British Journal of Pharmacology</i> , 2004, 141, 1077-1083.	2.7	27
79	Arachidonic acid relaxes human pulmonary arteries through K ⁺ channels and nitric oxide pathways. <i>European Journal of Pharmacology</i> , 2004, 501, 127-135.	1.7	10
80	Association between concomitant use of several systemic NSAIDs and an excess risk of adverse drug reaction. A case/non-case study from the French Pharmacovigilance system database. <i>European Journal of Clinical Pharmacology</i> , 2004, 60, 279-83.	0.8	17
81	Effect of chronic intake of NSAIDs and cyclooxygenase 2-selective inhibitors on esophageal cancer incidence. <i>Clinical Gastroenterology and Hepatology</i> , 2004, 2, 880-887.	2.4	43
82	Treatment Costs to Prevent or Treat Upper Gastrointestinal Adverse Events Associated with NSAIDs. <i>Drug Safety</i> , 2004, 27, 1019-1042.	1.4	21
83	The cyclooxygenase-2-selective inhibitors rofecoxib and celecoxib prevent colorectal neoplasia occurrence and recurrence. <i>Gastroenterology</i> , 2003, 125, 404-412.	0.6	91
84	Neurokinins Induce Relaxation of Human Pulmonary Vessels Through Stimulation of Endothelial NK1 Receptors. <i>Journal of Cardiovascular Pharmacology</i> , 2003, 41, 343-355.	0.8	15
85	ETA, Mixed ETA/ETB Receptor Antagonists, and Protein Kinase C Inhibitor Prevent Acute Hypoxic Pulmonary Vasoconstriction: Influence of Potassium Channels. <i>Journal of Cardiovascular Pharmacology</i> , 2003, 41, 117-125.	0.8	15
86	Magnetic Resonance Cholangiopancreatography. <i>Annals of Internal Medicine</i> , 2003, 139, 547.	2.0	374
87	Consensus Recommendations for Managing Patients with Nonvariceal Upper Gastrointestinal Bleeding. <i>Annals of Internal Medicine</i> , 2003, 139, 843.	2.0	458
88	Excessive alcohol consumption favours high risk polyp or colorectal cancer occurrence among patients with adenomas: a case control study. <i>Gut</i> , 2002, 50, 38-42.	6.1	57
89	Relaxant Effects of Selective Phosphodiesterase Inhibitors on U46619 Precontracted Human Intralobar Pulmonary Arteries and Role of Potassium Channels. <i>Journal of Cardiovascular Pharmacology</i> , 2002, 40, 153-161.	0.8	18
90	Hypoxic Vasoconstriction of Rat Main Pulmonary Artery: Role of Endogenous Nitric Oxide, Potassium Channels, and Phosphodiesterase Inhibition. <i>Journal of Cardiovascular Pharmacology</i> , 2001, 38, 325-334.	0.8	16

#	ARTICLE	IF	CITATIONS
91	Non-steroidal anti-inflammatory drug prescribing patterns in general practice: comparison of a general practitioner-based survey and a pharmacy-based survey in France. <i>Pharmacoepidemiology and Drug Safety</i> , 2001, 10, 329-338.	0.9	15
92	Non-steroidal anti-inflammatory and cytoprotective drug co-prescription in general practice. <i>European Journal of Clinical Pharmacology</i> , 2001, 57, 737-743.	0.8	28
93	Effects of phosphodiesterase inhibitors on hypoxic pulmonary vasoconstriction. Influence of K ⁺ channels and nitric oxide. <i>European Journal of Pharmacology</i> , 2001, 417, 141-148.	1.7	7
94	Functional, biochemical and molecular biological evidence for a possible $\hat{\iota}^2_3$ -adrenoceptor in human near-term myometrium. <i>British Journal of Pharmacology</i> , 2000, 130, 1960-1966.	2.7	49
95	Role of potassium channels and nitric oxide in the relaxant effects elicited by $\hat{\iota}^2$ -adrenoceptor agonists on hypoxic vasoconstriction in the isolated perfused lung of the rat. <i>British Journal of Pharmacology</i> , 1999, 127, 421-428.	2.7	17
96	Pharmacological and biochemical study on the effects of selective phosphodiesterase inhibitors on human term myometrium. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 1999, 360, 457-463.	1.4	21
97	In vitro inhibition of human colonic motility with SR 59119A and SR 59104A: evidence of a $\hat{\iota}^2_3$ -adrenoceptor-mediated effect. <i>European Journal of Pharmacology</i> , 1998, 353, 281-287.	1.7	28